<DOC>
	<DOCNO>NCT01915901</DOCNO>
	<brief_summary>The primary objective study determine effect bismuth subsalicylate ( Pepto-Bismol® ) 524 mg versus placebo gastrointestinal ( GI ) -related event report healthy volunteer receive TECFIDERA™ ( dimethyl fumarate [ DMF ] ; also know BG00012 ) twice daily ( BID ) The secondary objective study study population : To characterize effect bismuth subsalicylate ( Pepto-Bismol® ) 524 mg versus placebo frequency , severity , duration GI-related event evaluate GI-related event lead discontinuation DMF .</brief_summary>
	<brief_title>PeptoBismol® Use Reduce Gastrointestinal Events Healthy Volunteers Receiving DMF Tecfidera® Twice Daily</brief_title>
	<detailed_description />
	<mesh_term>Bismuth</mesh_term>
	<mesh_term>Bismuth subsalicylate</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Must good health determine Principal Investigator ( PI ) base medical history Screening evaluation ( clinical laboratory evaluation , 12lead electrocardiogram ( ECG ) , vital sign ; see specific exclusion criterion ) . Must body mass index ( BMI ) 18.0 34.0 kg/m2 , inclusive . Subjects reproductive potential ( include male ) must practice effective contraception study willing able continue contraception 90 day last dose study drug . Male subject must agree donate sperm 90 day last dose study drug . Must naïve dimethyl fumarate ( DMF ) fumaric acid ester . Key History positive result Screening visit HIV . History positive result Screening visit hepatitis C virus antibody hepatitis B virus ( define positive hepatitis B surface antigen [ HBsAg ] hepatitis B core antibody [ HBcAb ] ) . History clinically significant gastrointestinal ( GI ) disease determine PI ( include Crohn 's disease , peptic ulcer disease , ulcerative colitis , confirm diagnosis irritable bowel syndrome ) active GI disease ongoing symptom . History severe allergic anaphylactic reaction , consider clinically relevant PI . Known allergy PeptoBismol® , salicylates , nonsteroidal antiinflammatory drug , consider clinically relevant PI . Female subject pregnant base result serum pregnancy test Screening currently breastfeed . Current enrollment study treatment disease study . Receipt investigational drug within 5 halflives 30 day , whichever longer , prior study entry . History alcohol abuse substance abuse ( determine PI ) within previous 5 year , positive urine drug/alcohol test Screening , alcohol use prior screen visit . Regular use tobacco product , define smoke smokeless product use equivalent &gt; 5 cigarettes/day consecutive week , within 3 month prior Day 1 . Other unspecified reason , opinion PI Biogen Idec , make subject unsuitable enrollment . Other protocoldefined Inclusion/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>